-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of NMPA showed that Chia Tai Tianqing's gadolinium disodium injection passed the consistency evaluation of generic drugs, and it was the second company to review the product
.
Disodium gadoxetate is a magnetic resonance contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 200 million yuan, a year-on-year increase of 36.
83%
.
At present, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
has already reviewed 49 products
.
Gadoxetate disodium is a liver-specific magnetic resonance contrast agent developed by Bayer, which can help display the structure and patency of the biliary system inside and outside the liver, understand the function of liver cells, and characterize different types of liver damage
.
This product is helpful for the detection of liver lesions, especially can improve the detection rate of small liver tumors, and is helpful for the early diagnosis and treatment of liver lesions
.
According to data from Meinnet.
com, in 2020, the sales of disodium gadolinium disodium in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 200 million yuan, an increase of 36.
83% year-on-year; 2021H1 Its sales exceeded 100 million yuan, a year-on-year increase of 52.
26%, and CP Tianqing Pharmaceuticals has occupied 20% of the market share
.
Sales of Disodium Gadolinium Disodium in Public Medical Institutions in China (Unit: RMB 10,000) Source: Meine.
com.
Competitive Pattern of Terminal Gadolinium Disodium in Public Medical Institutions in China In June 2019, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
imitated 6 types of gadolinium disodium reported for production Sodium injection was approved for marketing and became the first domestic imitation; in September 2020, Chia Tai Tianqing Pharmaceutical submitted a supplementary application for the consistency evaluation of gadolinium disodium injection; in September 2021, Kelun Pharmaceutical submitted a generic 4 category report The produced gadoxetate disodium injection was batch-produced and deemed to have been reviewed, becoming the first company to have reviewed the product
.
With the approval of the supplementary application for the consistency evaluation of the product, CP Tianqing Pharmaceutical became the second company to pass the evaluation of the product
.
Up to now, CP Tianqing Pharmaceuticals has passed/deemedly passed the consistency evaluation of 49 varieties (69 product regulations), of which 20 varieties are the first in China to have passed the evaluation
.
In the field of contrast agents, CP Tianqing Pharmaceuticals has already reviewed two products, including iodixanol injection and gadolinium disodium injection
.
Data source: Mi Neiwang database, NMPA
.
Disodium gadoxetate is a magnetic resonance contrast agent.
In 2020, the terminal sales of public medical institutions in China will exceed 200 million yuan, a year-on-year increase of 36.
83%
.
At present, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
has already reviewed 49 products
.
Gadoxetate disodium is a liver-specific magnetic resonance contrast agent developed by Bayer, which can help display the structure and patency of the biliary system inside and outside the liver, understand the function of liver cells, and characterize different types of liver damage
.
This product is helpful for the detection of liver lesions, especially can improve the detection rate of small liver tumors, and is helpful for the early diagnosis and treatment of liver lesions
.
According to data from Meinnet.
com, in 2020, the sales of disodium gadolinium disodium in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 200 million yuan, an increase of 36.
83% year-on-year; 2021H1 Its sales exceeded 100 million yuan, a year-on-year increase of 52.
26%, and CP Tianqing Pharmaceuticals has occupied 20% of the market share
.
Sales of Disodium Gadolinium Disodium in Public Medical Institutions in China (Unit: RMB 10,000) Source: Meine.
com.
Competitive Pattern of Terminal Gadolinium Disodium in Public Medical Institutions in China In June 2019, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
imitated 6 types of gadolinium disodium reported for production Sodium injection was approved for marketing and became the first domestic imitation; in September 2020, Chia Tai Tianqing Pharmaceutical submitted a supplementary application for the consistency evaluation of gadolinium disodium injection; in September 2021, Kelun Pharmaceutical submitted a generic 4 category report The produced gadoxetate disodium injection was batch-produced and deemed to have been reviewed, becoming the first company to have reviewed the product
.
With the approval of the supplementary application for the consistency evaluation of the product, CP Tianqing Pharmaceutical became the second company to pass the evaluation of the product
.
Up to now, CP Tianqing Pharmaceuticals has passed/deemedly passed the consistency evaluation of 49 varieties (69 product regulations), of which 20 varieties are the first in China to have passed the evaluation
.
In the field of contrast agents, CP Tianqing Pharmaceuticals has already reviewed two products, including iodixanol injection and gadolinium disodium injection
.
Data source: Mi Neiwang database, NMPA
